The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

If you have been diagnosed with metastatic breast cancer, resources like support groups, counseling, financial assistance, and online communities can help.

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...